Literature DB >> 21482330

[Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis].

B Wallaert1, A Guetta, L Wemeau-Stervinou, G Tercé, M Valette, R Nevière, B Aguilaniu.   

Abstract

Current guidelines for referring patients with idiopathic pulmonary fibrosis (IPF) for lung transplantation, based on resting parameters, are insufficient to predict 3-year mortality. The aim of this study was to determine the prognostic value of cardio-pulmonary exercise testing (CPET) in patients with IPF. A multicentre retrospective study of 3-year outcome was made on 63 adult patients with IPF who underwent CPET with blood gas analysis. Demographic data, resting pulmonary function and CPET parameters were collected to perform a univariate survival analysis. To estimate prognosis at 3 years, a multivariate logistic regression analysis by Kaplan-Meier curves and log-rank tests was performed. Forty-four patients (70%) were alive without lung transplant at the end of the 3-year follow-up: 19 patients (30%) were dead (n=14) or transplanted (n=5). Univariate analysis indicated that: at rest lower TLC, FVC, DLCO and PaCO(2), higher alveolo-arterial gradient for oxygen [P(A-a)O(2)] and pH; at ventilatory threshold (VT) higher VE/VO(2) and VE/VCO(2) and at peak exercise higher VE/VO(2) and VE/VCO(2), higher pH and ΔP(A-a)O(2)/ΔVO(2) (mmHg/L), lower VO(2) peak, PaO(2) and VO(2)/FC were associated with a significantly lower survival at 3 years. The multivariate logistic regression analysis showed that CPT (<65%) and VE/VO(2) at VT (>45) were independently associated with a lower survival at 3 years. Restriction and hyperventilation at ventilatory threshold are major prognostic factors in the course of IPF. CPET with blood gas analysis may have a prognostic value in these patients and initial evaluation of these parameters can help to predict disease progression.
Copyright © 2011 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482330     DOI: 10.1016/j.rmr.2010.08.016

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  6 in total

1.  Value of Cardiopulmonary Exercise Testing in the Prognosis Assessment of Chronic Obstructive Pulmonary Disease Patients: A Retrospective, Multicentre Cohort Study.

Authors:  Ralf Ewert; Anne Obst; Andreas Mühle; Michael Halank; Jörg Winkler; Bernd Trümper; Gerhard Hoheisel; Andreas Hoheisel; Mark Wiersbitzky; Alexander Heine; Alexander Maiwald; Sven Gläser; Beate Stubbe
Journal:  Respiration       Date:  2021-11-19       Impact factor: 3.966

2.  8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Jonathan Myers; Avraham Unterman; Shimon Izhakian; Jose Oliveira
Journal:  Lung       Date:  2019-01-02       Impact factor: 2.584

3.  Cardiopulmonary Exercise Testing Allows Discrimination Between Idiopathic Non-specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in Mild to Moderate Stages of the Disease.

Authors:  Lars Hagmeyer; Simon Herkenrath; Norbert Anduleit; Marcel Treml; Winfried Randerath
Journal:  Lung       Date:  2019-11-01       Impact factor: 2.584

4.  The Role of Cardiopulmonary Exercise Test in IPF Prognosis.

Authors:  Christina Triantafillidou; Effrosyni Manali; Panagiotis Lyberopoulos; Likourgos Kolilekas; Konstantinos Kagouridis; Sotirios Gyftopoulos; Konstantinos Vougas; Anastasia Kotanidou; Manos Alchanatis; Anna Karakatsani; Spyros A Papiris
Journal:  Pulm Med       Date:  2013-10-31

5.  Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Shimon Izhakian; Ricardo M Lima; Jose Oliveira
Journal:  J Clin Med       Date:  2016-08-18       Impact factor: 4.241

6.  Value of Cardiopulmonary Exercise Testing in Prognostic Assessment of Patients with Interstitial Lung Diseases.

Authors:  Beate Stubbe; Till Ittermann; Anita Grieger; Charlotte Walther; Sven Gläser; Ralf Ewert
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.